MEIP News and Press, MEI Pharma Inc. From 05/30/23

2023-05-30 18:06:33 ET MEI Pharma ( NASDAQ: MEIP ) has received an unsolicited offer from a group wanting to take the company private. Shares are up ~10% in after-hours trading. The pharma said it received a non-binding proposal Tuesday from a group represented by Anso...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced in their 13-D filing of earlier today, to acquire all outstandi...

‒ Voruciclib alone or in combination with venetoclax was generally well tolerated with no significant myelosuppression ‒ – Encouraging preliminary efficacy signal demonstrated with voruciclib alone and at the first dose level with voruciclib in combination with venetoclax...

2023-05-11 17:12:54 ET MEI Pharma press release ( NASDAQ: MEIP ): Q3 Non-GAAP EPS of -$2.32 beats by $0.48 . Revenue of $5.89M (-39.2% Y/Y) beats by $5.43M . For further details see: MEI Pharma Non-GAAP EPS of -$2.32 beats by $0.48, revenue of $5.89M beat...

-- MEI Begins Fourth Fiscal Quarter with $112.0 Million in Cash -- MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2023, and highlighted recent corporate events...

2023-04-14 16:33:12 ET MEI Pharma ( NASDAQ: MEIP ) said its board of directors had approved a 1-for-20 reverse stock split. ( MEIP ) is trading 2% lower after the bell. The company's common stock undergoes split adjustment and will become available for trading on t...

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split. The Company’s common stock will open for trading on the Nasdaq Capital Market on Mond...

Oncology-focused clinical-stage biotechs MEI Pharma ( NASDAQ: MEIP ) and Infinity Pharmaceuticals ( NASDAQ: INFI ) announced a merger agreement Thursday to combine in an all-stock transaction. Per the terms, Infinity ( INFI ) will become a wholly owned subsidiary of M...

Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through...

MEI Pharma press release ( NASDAQ: MEIP ): Q2 GAAP EPS of $0.08 beats by $0.29 . Revenue of $32.74M (+79.7% Y/Y) beats by $29.4M . For further details see: MEI Pharma GAAP EPS of $0.08 beats by $0.29, revenue of $32.74M beats by $29.4M